Nobody has claimed this event yet.
Organizers who claim their event pages can update listing details, add photos, answer to reviews, view click reports and more.Claim your free event listing
Enhance Delivery, Pharmacokinetics & Pharmacodynamics Beyond the Barriers of the Brain, & Advance the Next Generation of Administration Technologies
With knowledge of brain barrier biology, precise modelling, and shuttle technologies accelerating at a rapid rate there has never been a more pivotal time in CNS therapeutics. The historic challenges of crossing the blood-brain-barrier present a key problem on the brink of solution with the recent critical approval in Japan by JCR Pharmaceuticals.
At the 4th Brain Barriers Summit, you will join industry experts in this discursive, resolution led forum aiming to answer the question: how can we get neurological drugs to target?
Navigating through translational concerns, pharmacodynamics and pharmacokinetics, quantifying barrier penetration, this meeting seeks to improve outcome measures as more and more companies are progressing their pipeline. At this summit you will meet and network with the decision makers and lead scientists from JCR Pharmaceuticals, Sanofi, Otsuka, Vertex, Noveome, Cerebral Therapeutics and ArunA Bio; all working to pursue this increasingly attainable goal.
As we gather the best minds in this ever-challenging field, from the likes of AbbVie, Novartis, Roche, Merck and Ossianix, join this intimate forum to be part of the conversation focused on enhancing drug delivery across the blood-brain barrier and network and build meaningful partnerships with over 80 blood-brain barrier specialists.
Artists / Speakers: Andrew Yang, Principal Investigator, Yang Lab UCSF, Bo Feng, Senior Director DMPK, Vertex Pharmaceuticals, Chaitali Ghosh, Associate Professor, Cleveland Clinic Lerner Research Institute, Habib Baghirov, Scientific Lead, Roche, Larry Brown, Executive Vice President & Chief Scientific Officer, Noveome Biotherapeutics, Lisa Shafer, Chief Scientific Officer, Cerebral Therapeutics, Gregory Stewart, Executive Consultant, Alchemy Neuroscience, Mansuo Hayashi, Chief Scientific Officer, Prevail Therapeutics, MaryPeace McRae, Associate Professor, Virginia Commonwealth University, Mathias Schmidt, President & Chief Executive Officer, JCR USA, Michelle Erickson, Research Assistant Professor, University of Washington, Patrick Schnider, Vice President Medicinal Chemistry, Rejuveron Life Sciences, Peter Westenskow, Section Head & Senior Scientist, Roche, Robert Stratford, Director Early Development & Translation, Otsuka, Robin Ji, Research Scientist, Columbia University, Jim Gorman, Principal Investigator, Wyss Institute Brain Targeting Program, Pawel Stocki, Director of Research, Ossianix, Sreeraj Macha, Senior Director, Sanofi, Steve Stice, Chief Executive Officer, ArunA Bio, Umar Iqbal, Research Scientist, National Research Council Canada, William Elmquist, Professor Department Pharmaceutics, University of Minnesota
Dates and Time: Starts: Mon, Aug 29, 2022 ( 9:00 AM) and Ends: Wed, Aug 31, 2022 ( 4:00 PM)
Reviews are public and modifiable.